

Cancer Prevention and Control CIRB Meeting Agenda

June 24, 2021

I. Amendment Prior to Activation

A222001, A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Men Receiving Androgen Deprivation Therapy (Protocol Version Date 05/12/21)

II. Continuing Review

A221505, RT Charm: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction (Protocol Version Date 01/19/21)

III. Continuing Review

EA1151, Tomosynthesis Mammographic Imaging Screening Trial (TMIST) (Protocol Version Date 08/11/20)

IV. Continuing Review

EA2185, Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs (Protocol Version Date 05/20/21)

V. Continuing Review

MDA2016-07-02, A Randomized, Double-blind, Placebo-controlled Study of 4-hydroxytamoxifen Topical Gel in Women with Mammographically Dense Breast (Protocol Version Date 07/06/20)

VI. Continuing Review

NWU20-01-03, Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): RELIEF-NAFLD (Protocol Version Date 05/05/21)

VII. Continuing Review

URCC-16070, Treatment of Refractory Nausea (Protocol Version Date 07/17/20)

VIII. New Study ReReview

A211901, Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions (Protocol Version Date 06/16/21)

IX. New Study - Initial Review

NWU20-04-01, Metformin for Chemoprevention of Lung Cancer in High-Risk Obese Individuals (Protocol Version Date 05/20/21)

X. Amendment ReReview

A221805, Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study (Protocol Version Date 06/16/21)
